Zofran Lawsuit: Ondanestron, Zofran ODT, Zuplenz
During the past decade Zofran and Zuplenz have been increasingly used in the United States for nausea and vomiting of pregnancy. The drugs act by blocking the actions of chemicals in the body causing nausea. The patent for Zofran expired in 2006 but Zuplenz was then approved in 2010. The main difference between Zofran and Zuplenz is that Zuplenz tablets will dissolve without water.
The drug indication is limited to patients following cancer treatments and surgery. However, the drugs have been routinely prescribed and used “off label” for stomach problems in children and morning sickness in expecting mothers. It has been estimated that 80 percent of pregnant women consume a version of Zofran or Zuplenz. In 2012, Glaxo Smith Kline plead guilty to fraud and illegal promotion of several drugs including Zofran and paid a $3 Billion fine as part of the Zofran Lawsuit settlement.
Joe Lyon has represented hundreds of individuals harmed by pharmaceutical products nationwide. For questions related to the Zofran lawsuit call for a no cost consultation (800) 513-2403.
Earlier studies on Zofran showed there was no safety issue with the drug. However, fetal safety data was based on less than 200 births. Newer research has called those conclusions into doubt with many questions related to the methodology applied to the data to reach such conclusions.
Following the NEJM study, the International Society of Pharmacoepidmiology published a paper entitled Ondanestron Use in Early Pregnancy and Risk of Congential Malformations evaluated women in the first trimester. The researchers found that after exposure to ondanestron, children were more likely to suffer a birth defect. Specifically, the strongest association was related heart defects involving cardiac tissue that failed to develop. Notably:
In December 2014 , a group of Swedish publish health officials published a paper entitled ” Use of Ondanestron During Pregnancy & Congenital Malformations in The Infant” evaluating a total of 1,349 births. The authors also concluded that there was a statistically significant increased risk of cardiovascular defects associated with Zofran.
A control study by Sloan Epidemiology unit and Centers for Disease Control found a 2 fold increase for cleft palate for Zofran taken in the first trimester [odds ratio = 2.37 (95% CI, 1.28-4.76).
In September of 2011, the FDA issued a warning about possible QT prolongation and torsade de pointes among people receiving Zofran and called for closer monitoring of patients who may suffer QT syndromes, electrolyte imbalances, or congestive heart failure.
If you or a loved one has suffered an injury due to a Zofran injury, and have questions about the root cause and the legal remedies available to improve quality of life and medical care, contact The Lyon Firm (800) 513-2403. You will speak directly with Mr. Lyon, and he will help you answer critical questions regarding a potential Zofran lawsuit.